Back to search results

CanScan: Community Registry for Cancer Screening and Prevention

This study, called CanScan, is creating a registry to better understand and improve cancer screening and prevention. It aims to collect information from 10,000 people to help with early cancer diagnosis, which can lead to better treatment and survival. You can join if you are an adult (18 or older) and have a family or personal history that suggests you might be at a higher risk for cancer. The main goal is to track the rate of specific genetic changes (Pathogenic Germline Variants, or PGV) linked to cancer risk over 10 years. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information from participants without providing any specific interventions. It plans to enroll 10,000 participants.
What's involved
You would provide data through questionnaires. The registry will also use information from your non-research assessments if you agree.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 10 years from the time the study begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06804395

CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management

Recruiting
Not specifiedAges 18+Observational
Hackensack Meridian Health
~10,000 participants
Updated 2026-05-26 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of Pathogenic Germline Variants (PGV)
Measured over 10 years from study initiation as defined based on the date the first patient was enrolled.

Conditions

Cancer Risk

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
New Jersey1

Study leadership

  • Elias Obeid, MD, MPH · PRINCIPAL_INVESTIGATOR · Hackensack Meridian Health

Who to contact

Lee Ifhar, MSc, CCRP
[email protected]
862-657-4227
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Rate of Pathogenic Germline Variants (PGV)10 years from study initiation as defined based on the date the first patient was enrolled.

    Compare the number of detected PGVs as measured by a universal multi-gene panel, proactively, in a diverse community-based population of individuals. PGV rate will be compared to NCCN genetic testing criteria at baseline, and to longitudinal cancer outcomes.